Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02812875
Title A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Curis, Inc.
Indications

lymphoma

Advanced Solid Tumor

Therapies

CA-170

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.